Technical Analysis for OZEM - Roundhill GLP-1 & Weight Loss ETF
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 25.57 | 2.16% | 0.54 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | 2.16% | |
| Lower Bollinger Band Walk | Weakness | 2.16% | |
| Inside Day | Range Contraction | 2.16% | |
| Below Lower BB | Weakness | 2.16% | |
| Lower Bollinger Band Touch | Weakness | 2.16% | |
| Oversold Stochastic | Weakness | 2.16% | |
| New 52 Week Closing Low | Bearish | 3.40% |
| Alert | Time |
|---|---|
| Possible NR7 | about 17 hours ago |
| Up 2% | about 19 hours ago |
| 60 Minute Opening Range Breakout | about 19 hours ago |
| 2x Volume Pace | about 21 hours ago |
| 1.5x Volume Pace | about 21 hours ago |
Free Daily (Stock) Chart Reading
Roundhill GLP-1 & Weight Loss ETF Description
OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each companys public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.
Classification
Keywords: Weight Management Peptide Therapeutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.21 |
| 52 Week Low | 24.51 |
| Average Volume | 38,199 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 27.76 |
| 20-Day Moving Average | 27.01 |
| 10-Day Moving Average | 26.33 |
| Average True Range | 0.55 |
| RSI (14) | 34.21 |
| ADX | 24.23 |
| +DI | 18.45 |
| -DI | 41.30 |
| Chandelier Exit (Long, 3 ATRs) | 26.82 |
| Chandelier Exit (Short, 3 ATRs) | 26.21 |
| Upper Bollinger Bands | 29.12 |
| Lower Bollinger Band | 24.91 |
| Percent B (%b) | 0.16 |
| BandWidth | 15.57 |
| MACD Line | -0.71 |
| MACD Signal Line | -0.48 |
| MACD Histogram | -0.2283 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.20 | ||||
| Resistance 3 (R3) | 26.13 | 25.85 | 26.10 | ||
| Resistance 2 (R2) | 25.85 | 25.69 | 25.89 | 26.06 | |
| Resistance 1 (R1) | 25.71 | 25.59 | 25.78 | 25.78 | 26.02 |
| Pivot Point | 25.43 | 25.43 | 25.47 | 25.47 | 25.43 |
| Support 1 (S1) | 25.29 | 25.27 | 25.36 | 25.36 | 25.12 |
| Support 2 (S2) | 25.01 | 25.17 | 25.05 | 25.08 | |
| Support 3 (S3) | 24.87 | 25.01 | 25.05 | ||
| Support 4 (S4) | 24.94 |
